In APP transgenic mice (APP-NL-G-F knock-in mice) used to model AD pathology, 4D9 treatment significantly increased TREM2 expression on microglia and reduced Aβ plaque burden (146). This evidence concerns the gene TREM2 and Alzheimer disease.